Tarsus Pharmaceuticals (NASDAQ:TARS) General Counsel Bryan Wahl Sells 4,231 Shares of Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) General Counsel Bryan Wahl sold 4,231 shares of the business’s stock in a transaction dated Thursday, March 19th. The stock was sold at an average price of $67.00, for a total value of $283,477.00. Following the completion of the sale, the general counsel owned 63,959 shares in the company, valued at $4,285,253. This represents a 6.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Bryan Wahl also recently made the following trade(s):

• On Wednesday, March 18th, Bryan Wahl sold 4,125 shares of Tarsus Pharmaceuticals stock. The shares were sold at an average price of $68.71, for a total value of $283,428.75.
• On Tuesday, March 17th, Bryan Wahl sold 4,084 shares of Tarsus Pharmaceuticals stock. The stock was sold at an average price of $69.42, for a total value of $283,511.28.

Tarsus Pharmaceuticals Stock Down 2.2%

Shares of TARS opened at $66.75 on Friday. The stock has a market capitalization of $2.84 billion, a price-to-earnings ratio of -41.20 and a beta of 0.55. Tarsus Pharmaceuticals, Inc. has a 1 year low of $38.51 and a 1 year high of $85.25. The business’s 50 day simple moving average is $69.36 and its 200-day simple moving average is $70.18. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.85 and a quick ratio of 3.82.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its earnings results on Monday, February 23rd. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). Tarsus Pharmaceuticals had a negative net margin of 14.72% and a negative return on equity of 19.63%. The business had revenue of $151.67 million during the quarter, compared to analysts’ expectations of $144.56 million. As a group, equities analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year.

Key Headlines Impacting Tarsus Pharmaceuticals

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Lifesci Capital upgraded TARS to “Strong‑Buy” and published tighter quarterly and FY‑2026 EPS forecasts (smaller expected losses vs. consensus), which supports a more constructive growth/recovery thesis for the stock. Read More.
• Neutral Sentiment: Street consensus remains mixed-to-favorable (average “Moderate Buy”); Lifesci’s upgrade improves outlook but does not represent unanimous conviction across all analysts. Read More.
• Neutral Sentiment: Company fundamentals: most recent quarter showed a slight EPS miss (reported ($0.20) vs. ($0.19) estimate) but revenue beat, leaving fundamentals mixed and dependent on future trial/launch catalysts. Read More.
• Neutral Sentiment: High institutional ownership (~90%) is a double‑edged factor — it stabilizes float but means large holders can move the stock if they adjust positions. Read More.
• Negative Sentiment: Significant insider selling disclosed in multiple Form 4s between Mar 16–19: CEO Bobak Azamian sold ~10.9k–12.0k shares across several days (prices ~ $67–$69), director William J. Link sold 12,500 shares (~$68.79), and several other senior officers also reduced stakes — these large, clustered sales can create immediate downward pressure and raise questions about near‑term liquidity needs or portfolio rebalancing. Read More.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on TARS. Wall Street Zen downgraded shares of Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Barclays began coverage on shares of Tarsus Pharmaceuticals in a report on Monday, December 8th. They issued an “overweight” rating and a $100.00 price target for the company. Lifesci Capital raised Tarsus Pharmaceuticals to a “strong-buy” rating in a research note on Monday. Zacks Research downgraded Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 25th. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $68.00 price objective on shares of Tarsus Pharmaceuticals in a research note on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $91.83.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Deep Track Capital LP lifted its holdings in shares of Tarsus Pharmaceuticals by 71.4% in the 3rd quarter. Deep Track Capital LP now owns 3,000,000 shares of the company’s stock worth $178,290,000 after acquiring an additional 1,250,000 shares during the last quarter. Janus Henderson Group PLC grew its holdings in Tarsus Pharmaceuticals by 34.1% during the 4th quarter. Janus Henderson Group PLC now owns 1,930,325 shares of the company’s stock valued at $158,062,000 after purchasing an additional 491,326 shares during the last quarter. Norges Bank bought a new position in Tarsus Pharmaceuticals during the 2nd quarter valued at about $19,095,000. M&T Bank Corp raised its position in Tarsus Pharmaceuticals by 11,730.0% in the 4th quarter. M&T Bank Corp now owns 437,119 shares of the company’s stock worth $35,791,000 after purchasing an additional 433,424 shares during the period. Finally, MPM Bioimpact LLC purchased a new stake in Tarsus Pharmaceuticals in the 2nd quarter worth about $13,834,000. Hedge funds and other institutional investors own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.